Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

izokibep (ABY-035) - Affibody

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eadv/abstracts_congress_2025/61287.pdf

Kim A. Papp 1, 2; Falk G. Bechara 3; Martina L Porter 4; Seth Forman 5; Howard Sofen 6; Jacek Szepietowski 7; Benjamin D. Ehst 8; Antonio Martorell Calatayud 9; Shephard Mpofu 10; fredrik frejd 11; Alexa B. Kimball 4

Jun 13, 2025